Relief for Symptoms of Multiple Sclerosis

Dr. Bergeron has recently noted                significant results using mild hyperbaric oxygen therapy in the treatment of Multiple Sclerosis. Tremors, severe pain, blurred vision, weak limbs, numbness, and fatigue are just some of the symptoms of Multiple Sclerosis (MS), one of the most common diseases of the central nervous system. It is estimated that MS currently affects over 2,500,000 people worldwide. The American Wellness Institute has found new hope for those suffering with these debilitating diseases.               

        Dr. Bergeron has treated several MS patients using mild hyperbaric oxygen therapy (mHBOT), which enhances the metabolism and natural healing processes. mHBOT is administered by breathing an increased concentration of oxygen while lying inside a pressurized chamber.  Many times patients enter remission after undergoing hyperbaric therapy for a

nine-month period.  In some cases, in the initial stages of treatment, MS patients have seen sudden symptom resolution during the one-hour therapy session itself, with a slow slight return of the symptomology 4-5 hours after treatment.

      Due to our body's reliance on oxygen, it is not surprising that mHBOT assists the healing   process of injured tissues.  Recent scientific studies have shown inflammation and tissue swelling inhibits the delivery of oxygen and can lead to what is known as ”MS Flair".  By increasing the amount of oxygen in the system, scarring and plaque formation is lessened, swelling reduced, and the body's natural healing processes are increased.  Patients have found that spasticity, pain, dizziness, tremors, ability to move limbs that were previously immobile, have all disappeared during this time. 

     Dr. Bergeron states "There seems to be some cascade of events that is occurring during mHBOT sessions that is causing a transient change in                  symptomology.  Since these patients have traditionally been difficult treat and show slow symptom resolution,

these findings are very significant in the use of mHBOT on MS."  He further theorized that patients, who experience this release of symptoms during an initial treatment, might have heavy metal, chemical exposure, or other pathogenic process to contend with. The hyperbaric chamber also works to assist in detoxifying the   system by forcing oxygen into the system and creating a pressurized environment, which then drives toxins from the system.

    In many scientific studies, hyperbaric therapy has been shown to control MS symptoms, and in some cases, halt the advancement of the disease. While mHBOT has shown great relief from symptomology without serious side effects as seen with pharmaceuticals, its effects differ from patient to patient.

“In some cases, MS patients have seen sudden symptom resolution during the one-hour therapy               session itself…”

Multiple Sclerosis Study Abstracts Utilizing Hyperbaric Oxygen Therapy

Genox Medical Equipment

We specialize in medical            technologies and products for both personal and clinical use.

·         Portable Hyperbaric Chambers

·         High Pressure             Hyperbaric Chambers

·         Far Infrared Sauna

·         Used Hyperbaric Chambers

We are committed to providing cutting edge medical equipment for developments in both               conventional and alternative medicine.

www.GenoxInc.com

Email: info@genoxinc.com

MS its etiology, pathogenesis, and therapeutics with emphasis on the              controversial use of HBO2

Journal Hyperbaric Medicine 1988; 3(3):143-164 Gottlieb SF, Neubauer RA.

   Abstract: A review of the current hypotheses in the etiology and pathogenesis of multiple sclerosis (MS) is presented together with the implications for therapy. A new hypothesis as to etiology is presented. Special emphasis is placed on the controversy surrounding the use of hyperbaric oxygen in a critical analysis of the published double-blind studies and related discussions.  It is concluded that the evidence of beneficial effects of hyperbaric oxygen therapy, despite the use of patients with advanced disease in trials, is very impressive, especially in chronic progressive disease. It is also concluded that there is need for further research and that such studies should examine the effects of hyperbaric oxygenation alone, and in combination with other therapeutic agents, in individual patients with the methods of real-time investigation now available. Meanwhile, based on comparative efficacy and safety, hyperbaric oxygenation is recommended for treating early stages of MS, especially for treating cerebellar and bowel-bladder disorders. ACTH-cortisone, antiviral agents, co-polymer 1, double-blind studies, hyperbaric oxygen therapy, immunosuppressants, Kurtzke disability scores, MS etiology, MS pathophysiology MS therapy, multiple sclerosis (MS), plasmapheresis.

Hyperbaric-oxygen treatment of multiple sclerosis. A randomized, placebo-controlled, double-blind study.

N Engl J Med 1983 Jan 27;308(4):181-6 Fischer BH, Marks M, Reich T.

Abstract: Several uncontrolled studies have suggested a beneficial effect of hyperbaric oxygen on multiple sclerosis. We studied 40 patients with advanced chronic multiple sclerosis who were randomly divided into two matching groups. The experimental group received pure oxygen, and the placebo group received a mixture of 10 per cent oxygen and 90 per cent nitrogen; both groups were treated at a pressure of 2 atmospheres absolute for 90 minutes once daily, for a total of 20 exposures. Objective improvement occurred in 12 of 17 patients treated with hyperbaric oxygen and in 1 of 20 patients treated with placebo (P less than 0.0001). Improvement was transient in seven of the patients treated with oxygen and long-lasting in five. Those with less severe forms of the disease had a more favorable and lasting response. At one year of follow-up, deterioration was noticed in 2 patients (12 per cent) in the oxygen group, neither of whom had had an initial response, and in 11 patients (55 per cent) in the placebo group.

Publication Types: Clinical Trial, Randomized Controlled Trial, PMID: 6336824